NanoViricides’ drug FluCide found safe in small animal studies

October 24, 2013 bjohnson56 0

Early results for the new flu drug FluCide® found to be safe in a non-GLP small animal safety/ toxicology study. These preliminary results support the company’s earlier reports of the FluCide® drug being effective in animal models of different influenza A virus strains. NanoViricides is also developing drugs against HIV/AIDS (HivCide™-I), Dengue (DengueCide™-I), and External Eye Viral disease (EKC-Cide™-I), amongst other viral diseases.

Okairos: Okay After All

June 5, 2013 OneMedPlace Team 0

On May 29th, 2013, GlaxoSmithKline (GSK) announced the acquisition of Okairos in an all-cash deal worth $325 million US. The Okairos acquisition helps complement the pharma giant’s existing vaccine technology and expertise and will enable GSK to continue its work developing the next generation of vaccines.

No Image

Special Report: Fighting the U.S. AIDS Epidemic

July 16, 2009 vanderson 4

An estimated 1.2 million people in the U.S. have the HIV virus. OneMedPlace speaks with AIDS advocate Michael Manganiello about the scope of the epidemic, the possibility of a vaccine, and what needs to happen to make a national AIDS strategy a reality.